SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Scinai Immunotherapeutics Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026

$0.75−0.00 (-0.32%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Scinai Immunotherapeutics Ltd. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	1.31	0.66	–	–	–	–	–	–	–	–	–
Cost of Revenue	3.96	1.24	–	–	–	–	–	–	–	–	–
Gross Profit	-2.65	-0.58	–	–	–	–	–	–	–	–	–
Research & Development	2.37	5.53	5.21	5.77	3.25	16	–	–	5.42	–	–
Selling, General & Admin	2.52	2.53	4.51	5.30	7.63	–	–	–	1.41	–	–
General & Administrative	–	–	–	1.50	2.43	–	–	–	–	–	–
Operating Expenses	4.89	8.06	9.71	11	11	–	–	–	6.82	–	–
Operating Income	-7.54	-8.64	-9.71	-11	-11	–	–	–	–	–	–
Interest Expense	–	–	0.34	0.35	0.34	4.86	–	–	3.15	–	–
Interest & Investment Income	–	–	–	–	1.84	1.20	–	–	0.01	–	–
Other Non-Operating Income	-0.77	-1.33	3.21	5.27	2.66	–	–	–	–	–	–
Income from Continuing Operations	–	–	–	8.13	3.15	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	-13	-1.39	–	–	-9.97	–	–
Net Income	-8.31	4.80	-6.50	-5.80	-8.21	–	–	–	–	–	–
Net Income to Common	–	–	6.50	5.80	8.21	–	–	–	–	–	–
EPS (Basic)(per share)	–	–	0.0040	0.01	-0.02	–	-0.33	–	-0.05	–	–
EPS (Diluted)(per share)	–	–	0.0040	0.01	-0.02	–	-0.33	–	-0.05	–	–
Shares Outstanding (Basic, Weighted)(shares)	9,339	3,225	1,563	754	565	443	327	261	201	135	106
Shares Outstanding (Diluted, Weighted)(shares)	9,339	3,225	1,563	754	565	443	327	261	201	135	106
EBITDA	-6.12	-6.99	-9.19	-10	-10	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: -202.3%
Operating margin: -575.3%
Net margin: -633.6%
Return on equity, FY2025: -91.9%

Financial strength

Current ratio: 1.56
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 118.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –